Ivermectin as a therapeutic alternative in neurocysticercosis that is resistant to conventional pharmacological treatment

Article de journal


Auteurs / Editeurs


Domaines de Recherche

Pas d'articles correspondants trouvés.


Détails sur la publication

Liste des auteurs: Diazgranados-Sanchez JA, Barrios-Arrazola G, Costa JL, Burbano-Pabon J, Pinzon-Bedoya J
Editeur: Cesar Viguera
Année de publication: 2008
Journal: Revista de Neurologia (0210-0010)
Numéro du volume: 46
Numéro de publication: 11
Page d'accueil: 671
Dernière page: 674
Nombre de pages: 4
ISSN: 0210-0010
Languages: Anglais-Royaume-Uni (EN-GB)


Résumé

Introduction. Neurocysticerosis is a public health problem that can be found in many parts of the world, especially in developing countries, and today's high rates of immigration are making ti increasingly more common in developed countries. Cysticidal treatment of neurocysticercosis is a controversial issue because it is only partially effective against vesicualr and collodial-shaped cysts when the parasite persists after a course of albendazole or praziquantel, the only two therapeutic options that are currently available. ivermectin is a very effective, safe verterinary and human antiparasitic drug, with occasional very mild side effects. It has been used for over 25 years in cases of ectoparasitoses. such as pediculolsis capitis and myasis. It acts in the myonural junction on the receptors in the chloride channel by increasing their permeability and causing paralysis in adult worms or y a mediated immune mechanism when it acts on immature forms. Case reports, we report the cases of four patients who were previoulsy treated with albendazole reiteratively with radiological evidence. which shows the persistence of vaible vesicular or colloidial-shaped cysts. These patients were given 10 mg/day of ivermectin for 15 consecutive days or 10 mg/days as an average for 30 days, with excellent clinial and radiological progress. Conclusions. ivermectin was effective and did not give rise to any side effects when used to treat these four patients, who were resistant to conventional treatment with albendazole and/or praziquantel.


Mots-clés

Pas d'articles correspondants trouvés.


Documents

Pas d'articles correspondants trouvés.

Dernière mise à jour le 2019-23-08 à 11:15